ESTRO 2022 - Abstract Book

S388

Abstract book

ESTRO 2022

BT department till discharge was 8:55 (8:00-9:25). For the separate steps, the durations are shown in Figure 1. The target & OAR delineation and applicator reconstruction are done concurrently while the patient is waiting before treatment. A health state index score of 0.82 (0.67-1.00) was calculated from individual health profiles of the EQ-5D using a specific value set of the Netherlands. The EQ VAS score was 0.80 (0.63-0.88). During 20 of the 28 fractions, patients had no to slight pain at the beginning of the day, and during 18 of the 28 fractions, patients had no to slight anxiety. During treatment, patients had the highest pain score during waiting before treatment (3 (1-7)), the highest anxiety score during applicator removal (2.5 (0-8)), and the highest duration score for waiting before treatment (6 (0-7.5)). Figure 2 gives an overview of scores in different steps. The large variations in scores points at inter- and intra-patient variations. Conclusion This time-action analysis highlights the importance of logistics between different steps during cervical cancer brachytherapy. Pain, and anxiety scores were found to be highest during waiting time before treatment and applicator removal with large inter- and intra-patient variations. In the future, the time-action and patient experience analysis can be used to optimise different steps of the brachytherapy treatment.

OC-0445 Automated optimization for cervix brachytherapy requires more than the EMBRACE-II planning aims

L. Dickhoff 1 , E.M. Kerkhof 1 , B.R. Pieters 2 , H. Westerveld 2 , L.J. Stalpers 2 , L.A. Velema 1 , D.L. Barten 2 , H. Gratama van Andel 3 , Y. Niatsetski 3 , C.L. Creutzberg 1 , P.A. Bosman 4 , T. Alderliesten 1 1 Leiden University Medical Center, Radiation Oncology, Leiden, The Netherlands; 2 Amsterdam UMC University of Amsterdam, Radiation Oncology, Amsterdam, The Netherlands; 3 Elekta, Brachytherapy, Veenendaal, The Netherlands; 4 Centrum Wiskunde & Informatica, Life Sciences and Health, Amsterdam, The Netherlands Purpose or Objective A bi-objective optimization model was recently introduced that entails direct optimization on dose volume indices (DVIs) specified in a clinical protocol. Optimizing this model gives a set of treatment plans that represents trade-offs between target coverage and organ sparing, which was shown to include clinically desirable plans for prostate HDR BT. We studied the direct extension of this approach to cervical cancer BT, by optimizing BT planning aims recommended by the EMBRACE- II protocol.